Home › Free Stock Grades › CSTL
Castle Biosciences, Inc. (CSTL) Stock Grade
CSTL · Healthcare
C+
Market Cap
$1.1B
P/E Ratio
—
Revenue Growth (YoY)
+3.7%
Net Margin
-7.0%
Return on Equity
—
Dividend Yield
None
About Castle Biosciences, Inc.'s fundamentals
Castle Biosciences is a diagnostic company with a market capitalization of $1.1 billion that generated 3.7% year-over-year revenue growth in its latest period. The company is currently unprofitable with a net margin of -7.0% and reported a net loss in its latest annual statement, though it maintains positive free cash flow despite these accounting losses. The company does not pay a dividend and lacks sufficient earnings to calculate meaningful profitability ratios like P/E and return on equity.